Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
Background—Various antidepressant agents are metabolized by the CYP2C19 enzyme, including Citalopram and Escitalopram. Variation in CYP2C19 expression might give rise to different plasma concentrations of the active metabolites, potentially affecting both drugs’ efficacy and tolerability. Aim—The ai...
Shranjeno v:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2023-12-01
|
| Serija: | Biomedicines |
| Teme: | |
| Online dostop: | https://www.mdpi.com/2227-9059/11/12/3245 |
| Oznake: |
Brez oznak, prvi označite!
|